Craig-Hallum Maintains Myomo(MYO.US) With Buy Rating
Lake Street Maintains Myomo(MYO.US) With Buy Rating, Maintains Target Price $7.5
Lake Street Keeps Their Buy Rating on Myomo (MYO)
Craig-Hallum Initiates Myomo(MYO.US) With Buy Rating
Myomo Analyst Ratings
Myomo Analyst Ratings
Myomo Inc.: Strong Performance and Growth Prospects Justify Buy Rating
Myomo Inc.: Strong Q2 Performance and Positive Growth Outlook Justify Buy Rating
Lake Street Reaffirms Their Buy Rating on Myomo (MYO)
Craig-Hallum Maintains Myomo(MYO.US) With Buy Rating
Craig-Hallum Maintains Myomo(MYO.US) With Buy Rating
Craig-Hallum Initiates Myomo(MYO.US) With Buy Rating, Announces Target Price $7
Myomo Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Myomo (MYO) and Accolade (ACCD)
Myomo Analyst Ratings
Lake Street Starts Myomo With Buy Rating, $7 Price Target
Myomo's Strategic Turnaround: A Buy Rating With Revenue Growth and Operational Scaling on the Horizon
Myomo Analyst Ratings
Myomo's Strong Growth Potential Amid New CMS Guidelines Elicits a Buy Rating
Myomo Inc.: Strong Growth and Regulatory Tailwinds Support Buy Rating
No Data
No Data